Erythema multiforme after treatment with sorafenib

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Sorafenib is an oral chemotherapeutic agent used for solid tumors.
• Adverse cutaneous drug reactions are common with sorafenib, affecting up to 90% of patients.
• Erythema multiforme is an infrequent, delayed-type hypersensitivity reaction associated with sorafenib.

Observation:

• This report details a pediatric case of sorafenib treatment.
• The patient had a retrosternal desmoid tumor.
• Widespread erythema multiforme developed during treatment.

Findings:

• The child experienced extensive erythema multiforme.
• The reaction involved extremities, trunk, face, and mucosal membranes.
• This illustrates a severe cutaneous adverse event in a pediatric patient.

Implications:

• This case underscores the potential for severe dermatological side effects of sorafenib, even in pediatric populations.
• Awareness of erythema multiforme as a possible sorafenib reaction is crucial for timely diagnosis and management.
• Further research into predicting and mitigating severe cutaneous reactions to targeted therapies is warranted.